2000

The genesis

A unique cardiopoietic platform to be discovered at Mayo Clinic (USA).

Fundamental research is being conducted at Mayo Clinic (Rochester, Minnesota, USA) to unveil the mechanisms that make a stem cell differentiate into a heart cell. Prof. André Terzic Dr. Atta Behfar head the research.

2004

Start-up mindset

How to translate academic excellence into an innovative industrial project?

Cardio3 SA, the Company’s predecessor entity, was created by Michel Lussier, Christian Homsy, William Wijns and Jozef Bartunek to leverage research collaboration between Mayo Clinic and Cardiovascular Center Aalst in Belgium

2007

The Regenerative Medicine Era:

Positioning the Company as a global leader in cell therapy for ischemic heart failure.

Cardio3 SA becomes Cardio3 BioSciences SA and licenses the cardiac stem cell technology developed by Mayo Clinic to further develop C-Cure®.

2009

First patient treated with C-Cure®

The beginning of clinical testing of the Cardiopoiesis technology in human.

A first patient is being treated with C-Cure® in the Phase II clinical trial.

2010

Encouraging Phase II results

A great clinical milestone for a unique git cell therapy with CHART-1 in Europe.

Publication of the Phase II results for C-Cure® - significan`t functional and clinical benefits are demonstrated.